Eli Lilly's 3-step strategy to dominate the $95 billion obesity market

businessinsider.com/eli-lilly-3-step-strategy-dominate-95-billion-obesity-market-2025-7

Scientists at Eli Lilly are racing to develop new weight loss drugs that will be cheaper, stronger, or preserve more muscle mass.
Eli Lilly
Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.
The company is set to capture 50% of the $95 billion…

This story appeared on businessinsider.com, 2025-07-07 09:30:01.
The Entire Business World on a Single Page. Free to Use →